BPI Asia: China 2012

Bringing Together the Industry and Its Stakeholders!

As the biopharmaceutical industry in China continues to grow, the corresponding demand for high quality, tactical information and proven strategies continues to increase. While many perceive that China's current technologies and skillsets still lag behind that of their more advanced counterparts in US and Europe, or Korea and Japan, their thirst for knowledge and eagerness to adopt and adapt new techniques have enabled them to leap-frog their development in astonishing speed.

At IBC's 4th Annual BioProcess International™ China event, the goal is to bring China and the rest of the world together to explore the missing gaps in China's development, and to help bring China up-to-speed on critical areas such as cell line engineering, media development, product and process characterization, and most importantly, the capability to establish similarity between a biosimilar and its originator drug. The ultimate goal is to deliver strategies that will help improve the yield, quality and efficiency of production while reducing cost.

The conference will comprise of 2 parallel conference tracks:

-Cell Line Engineering, Cell Culture & Media Development

-Analytics and Quality - Characterization and Comparability for Biologics and Biosimilars

Plus, special focused sessions on:

-Biosimilars Development - Regulatory, Market, Clinical

-Virus Safety and Downstream Processing

-Facility Design and Disposables Manufacturing

Why You Should Attend:

International companies:

This is your gateway to meet and network with Chinese/Asian drug developers and contract manufacturers to understand where they stand in the field of processing capabilities, as well as find potential business partners and collaborators to develop biosimilars, biobetters, novel biologics or vaccines.

China-based companie